event-free survival
Fig. 3 · Panel Number_at_risk_in_CC_and_CT_combined
Panel Number_at_risk_in_CC_and_CT_combined 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Joseph Donovan, Nguyen Duc Bang, Huu Khanh Trinh Dong, Dang Trung Nghia Ho, Thi Anh Thu Nguyen, Thi Thu Hiep Nguyen, Hong Bao Ngoc Lam, Vo Khac Nguyen Phung, Truc Thanh Nguyen, Ho Hong Hanh Nguyen, Kieu Nguyet Oanh Pham, Dang Anh Thu Do, Thi Mai Trang Nguyen, Thi Minh Ha Dang, Huu Lan Nguyen, Van Vinh Chau Nguyen, Thanh Hai Hoang, Dinh Dinh Tran, Khanh Lam Phung, Lalita Ramakrishnan, Thanh Hoang Nhat Le, Thuy Thuong Thuong Nguyen, Marcel Wolbers, Evelyne Kestelyn, Ronald B Geskus, Hoan Phu Nguyen, Guy E Thwaites
Nat Med 32(3) 849-858
Adjunctive corticosteroids such as dexamethasone are recommended in tuberculous meningitis treatment, despite modest and heterogeneous survival benefit. Leukotriene A4 hydrolase (LTA4H) genotypes associate with distinct intracerebral inflammatory phenotypes and may determine corticosteroid response in tuberculous meningitis, with benefit observed in hyperinflammatory TT genotype but uncertain benefit in lower inflammation CC and CT genotypes. Here, in a phase 3, placebo-controlled trial of human immunodeficiency virus-negative Vietnamese adults with tuberculous meningitis, we randomized 613 LTA4H CC- and CT-genotype participants to 6-8 weeks of dexamethasone or placebo, aiming to show noninferiority of placebo (hazard ratio margin of 0.75) or its superiority. Given the significant survival benefit of dexamethasone previously seen in LTA4H TT-genotype individuals, TT-genotype participants all received open-label dexamethasone and were not randomized. A total of 89 TT-genotype participants received open-label dexamethasone. In CC- and CT-genotype participants, the primary endpoint of all-cause death or new neurological event over 12 months from randomization occurred in 108/305 (35.4%) given dexamethasone and 110/308 (35.7%) given placebo (hazard ratio of 0.99, 96% confidence interval (adjusted for multiple testing) 0.748-1.31). The number of observed primary endpoints (n = 218) exceeded the prespecified number (n = 184) used to calculate the trial's sample size and power. Placebo noninferiority was not established in the CC and CT population or in individual genotype subpopulations. Benefit or heterogeneity of effect was not observed by any prespecified subgroup. In TT-genotype participants, the primary endpoint occurred in 28/89 (31.5%) participants, similar to CC and CT participants. Outcomes were not significantly better in TT-genotype participants versus CC- or CT-genotype participants. In CC- and CT-genotype participants, serious adverse events occurred in 161/305 (52.8%) dexamethasone-treated participants and 160/308 (51.9%) placebo-treated participants. In conclusion, neither noninferiority nor superiority of placebo was established in human immunodeficiency virus-negative LTA4H CC- and CT-genotype adults with tuberculous meningitis, and dexamethasone was safe. The modest and heterogeneous benefit of dexamethasone indicates that greater understanding of tuberculous meningitis pathophysiology is needed, alongside better targeted, more effective anti-inflammatory agents than corticosteroids (ClinicalTrials.gov NCT03100786 ).
2 个 Figure · 9 个 KM 面板
Fig. 3. Death or new neurological events during the first 12 months after randomization for the intention-to-treat population. Kaplan–Meier curves are shown for the primary endpoint. The solid lines represent the estimated probability of event-free survival in each stratum. The colored shading represents the 95% CIs. A forest plot is shown displaying the hazard ratio (HR) and CIs, with corresponding confidence levels at 96% for CC and CT combined and 98.3% for CC. The points represent the estimated HRs in the primary endpoint between two treatment arms. The black lines represent the 95% CIs. The red vertical line demonstrates the noninferiority threshold at HR of 0.75. The dashed vertical line demonstrates the superiority threshold at HR of 1. For analysis, a Cox proportional hazard model was used, with MRC grade and LTA4H genotype as strata. Analyses are performed for the following populations: for CC and CT genotype combined, 613 participants; for CT genotype, 322 participants; and for CC genotype, 291 participants.
Fig. 3 · Panel Number_at_risk_in_CC_and_CT_combined
Panel Number_at_risk_in_CC_and_CT_combined 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel CC
Panel CC 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel CT
Panel CT 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. Death or new neurological events for all genotypes. A comparison of TT-genotype individuals receiving dexamethasone with CC, CC and CT, and CT-genotype individuals receiving dexamethasone. This is followed by comparison of TT-genotype individuals receiving dexamethasone with CC, CC and CT, and CT-genotype individuals receiving placebo. The solid lines represent the estimated probability of event-free survival in each stratum. The colored shading represents the 95% CIs. Analyses are performed for the following populations: TT-genotype participants receiving dexamethasone, 89; CC-genotype participants receiving dexamethasone, 146; CT-genotype participants receiving dexamethasone, 159; CC-genotype participants receiving placebo, 145; and CT-genotype participants receiving placebo, 163.
Fig. 4 · Panel CC
Panel CC 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel CC_and_CT
Panel CC_and_CT 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel CT
Panel CT 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel CC_4
Panel CC_4 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel CC_and_CT_5
Panel CC_and_CT_5 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel CT_6
Panel CT_6 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。